Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Finished Goods: 2021-2023

Historic Finished Goods for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Dec 2023 value amounting to $12.9 million.

  • Kiniksa Pharmaceuticals International's Finished Goods fell 15.85% to $12.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $12.9 million, marking a year-over-year decrease of 15.85%. This contributed to the annual value of $12.9 million for FY2023, which is 15.85% down from last year.
  • According to the latest figures from Q4 2023, Kiniksa Pharmaceuticals International's Finished Goods is $12.9 million, which was up 5.44% from $12.2 million recorded in Q3 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Finished Goods peaked at $19.9 million during Q2 2022, and registered a low of $1.4 million during Q3 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Finished Goods averaged around $10.4 million, with its median value being $12.5 million (2023).
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Finished Goods soared by 927.48% in 2022, and later decreased by 24.22% in 2023.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's Finished Goods (Quarterly) stood at $3.7 million in 2021, then soared by 315.97% to $15.3 million in 2022, then dropped by 15.85% to $12.9 million in 2023.
  • Its Finished Goods was $12.9 million in Q4 2023, compared to $12.2 million in Q3 2023 and $17.3 million in Q2 2023.